Sheetal Panday
Associate Director - Quantitative Pharmacology & Pharmacometrics, Immuno Oncology Merck & Co
Seminars
Wednesday 14th October 2026
Mechanistic QSP Platform for ADCs in Oncology: Exploring Prospective Efficacy & Safety Predictions to Guide Study Design
2:00 pm
- Integrating ADC MoA, target biology, payload dynamics, ADC/ICI disposition, and tumor–immune interactions with key clinical biomarkers
- Iteratively tuning QSP model with preclinical and clinical data to predict PK, efficacy and safety
- Simulating heterogeneous virtual populations to evaluate dosing strategies and therapeutic performance across ADCs and combinations
